HBV Citations List: February 2023

Literature Citations

1. Inhibition of Hepatitis B Virus (HBV) by Tachyplesin, a Marine Antimicrobial Cell-penetrating Peptide. Narula, P., S. Kiruthika, S. Chowdhari, P. Vivekanandan, and A. Chugh. Pharmaceutics, 2023. 15(2): p. 672-687. PMID[36839994]. PMCID[PMC9962029].
[PubMed]. HBV_02_2023.

2. Dihydromyricetin Inhibits Hepatitis B Virus Replication by Activating NF-kB, MAPKs, and Autophagy in Hepg2.2.15 Cells. Wang, X., H. Hu, B. Hu, H. Xia, X. Cheng, J. Zheng, Z. Zhang, and H. Liu. Molecular Biology Reports, 2023. 50(2): p. 1403-1414. PMID[36474061].
[PubMed]. HBV_02_2023.

3. Imide Cantharidin Derivatives: Synthesis and HBV-DNA Inhibitory Properties. Tan, C.B., Y.J. Xing, X.F. Qiao, B.M. Fan, X.L. Liu, and Y.B. Zeng. ScienceAsia, 2023. 49(1): p. 38-42. ISI[000912158300006].
[WOS]. HBV_02_2023.

4. Screening of an Epigenetic Compound Library Identifies BRD4 as a Potential Antiviral Target for Hepatitis B Virus Covalently Closed Circular DNA Transcription. Yu, X., Q. Long, S. Shen, Z. Liu, J. Chandran, J. Zhang, H. Ding, H. Zhang, D. Cai, E.S. Kim, Y. Huang, and H. Guo. Antiviral Research, 2023. 211: p. 105552. PMID[36737008].
[PubMed]. HBV_02_2023.

5. An O-Benzyl phosphonamidate Prodrug of Tenofovir for the Treatment of Hepatitis B Virus Infection. Zhang, Q.Q., Y.M. Peng, J. Hou, Y.H. Chen, B.J. Liu, P.H. Zhang, W.Q. Yu, and J.B. Chang. Journal of Medicinal Chemistry, 2022. 65(13): p. 9493-9505. PMID[35776695].
[PubMed]. HBV_02_2023.

Patent Citations

This month, no relevant HBV patents were identified.